Relay Therapeutics

RLAY

Market cap $4.34B

Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.

Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.

This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.

Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk.

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics.

Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink vascular malformations and improve symptoms ​in patients with rare vascular disorders.